X4 Pharma reports Q1 net loss of $51.8M; XOLREMDI approved for WHIM syndrome

X4 Pharmaceuticals, Inc

2024-Q1 EPS reported -$0.26

Net loss $51.8M vs $24.0M in Q1 2023; includes $13.8M non-cash loss on warrant liability.
Cash, equivalents, and securities $81.6M as of Mar 31, 2024; runway into 2025 excluding PRV monetization.
FDA approved XOLREMDI (mavorixafor) for WHIM syndrome in patients 12+ in late April 2024; U.S. launch underway.
Phase 2 interim data for mavorixafor in chronic neutropenia expected June 2024; Phase 3 trial planned in Q2 2024.
SG&A expenses rose to $17.4M from $7.2M due to commercial launch preparations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

X4 Pharmaceuticals, Inc reported for the first quarter ended March 31, 2024 results: net income $51.8 million.

Period: for the first quarter ended March 31, 2024
Net income: $51.8 million
Result: reported results

Exact text from the filing

X4 reported a net loss of $51.8 million for the first quarter ended March 31, 2024

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-020827

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.